Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Association of ApaI rs7975232 and BsmI rs1544410 in clinical outcomes of COVID-19 patients according to different SARS-CoV-2 variants
Al-Gharrawi et al., Scientific Reports, doi:10.1038/s41598-023-30859-7
Al-Gharrawi et al., Association of ApaI rs7975232 and BsmI rs1544410 in clinical outcomes of COVID-19 patients according to.., Scientific Reports, doi:10.1038/s41598-023-30859-7
Mar 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 3,184 patients in Iran, showing COVID-19 outcomes for specific variants were associated with genotypes of the ApaI rs7975232 and BsmI rs1544410 vitamin D receptor polymorphisms.
Al-Gharrawi et al., 3 Mar 2023, Iran, peer-reviewed, mean age 53.0, 3 authors, study period November 2020 - February 2022.
Contact: anvari_ph@yahoo.com, afateh2@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: www.nature.com/scientificreports OPEN Association of ApaI rs7975232 and BsmI rs1544410 in clinical outcomes of COVID‑19 patients according to different SARS‑CoV‑2 variants Ayad Naji Radha Al‑Gharrawi 1, Enayat Anvari 2* & Abolfazl Fateh 3,4* A growing body of research has shown how important vitamin D is in the prognosis of coronavirus disease 19 (COVID-19). The vitamin D receptor is necessary for vitamin D to perform its effects, and its polymorphisms can help in this regard. Therefore, we aimed to evaluate whether the association of ApaI rs7975232 and BsmI rs1544410 polymorphisms in different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants were influential in the outcomes of COVID-19. The polymerase chain reaction-restriction fragment length polymorphism method was utilized to determine the different genotypes of ApaI rs7975232 and BsmI rs1544410 in 1734 and 1450 patients who had recovered and deceased, respectively. Our finding revealed that the ApaI rs7975232 AA genotype in the Delta and Omicron BA.5 and the CA genotype in the Delta and Alpha variants were associated with higher mortality rate. Also, the BsmI rs1544410 GG genotype in the Delta and Omicron BA.5 and the GA genotype in the Delta and Alpha variants were related to a higher mortality rate. The A-G haplotype was linked with COVID-19 mortality in both the Alpha and Delta variants. The A-A haplotype for the Omicron BA.5 variants was statistically significant. In conclusion, our research revealed a connection between SARS-CoV-2 variants and the impacts of ApaI rs7975232 and BsmI rs1544410 polymorphisms. However, more research is still needed to substantiate our findings. The World Health Organization (WHO) reports demonstrate that severe acute respiratory syndrome associated with coronavirus-2 (SARS-CoV-2) has caused Coronavirus disease 2019 (COVID-19), a worldwide pandemic, in millions of people since December 2019. The symptoms of the COVID-19 can range from mild to moderate and severe to critical, necessitating hospitalization and intensive care unit (ICU) admissions for some p ­ atients1. It is appropriate to shift our focus from preventive to therapeutic measures in light of the development of effective vaccines against COVID-19, whose efficacies are unusually high but not absolute, and in light of the prospect that new viral variations may limit its efficacy. Additionally, there are still a significant number of unvaccinated ­people2. Vitamin D deficiency has increased the severity of viral illnesses such as ­influenza3. According to recent research, vitamin D can influence SARS-CoV-2 gene expression and reduce infection rate when it binds to the vitamin D response e­ lement4. The angiotensin-converting enzyme 2 (ACE2) mediates the SARS-CoV-2 infection and its receptor, which vitamin D. Additionally regulates, vitamin D is known to increase the generation of antimicrobial proteins, modulate innate and adaptive immune responses, and possibly operate as an antiinflammatory ­agent5–7. Vitamin D exerprimarily biological effects through vitamin D receptors (VDRs) are mostly found in the gastrointestinal tract, bones, lungs, and most immune cells. Even though the VDR is abundantly expressed in the lung tissue, it is yet unclear how vitamin D-VDR signaling may contribute to pulmonary i­ mmunopathology8. Regarding the related mechanisms, single nucleotide polymorphisms (SNPs) in the gene encoding the VDR could alter the protective efficacy of vitamin..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit